Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Summer has officially begun, but we are already counting down the days to our Early Detection of Cancer Conference in San Francisco, only three months away on 22-24 October.
Last year’s conference was a massive success, with tickets selling out in record time. Don’t miss your chance to attend this year and register now before it’s too late.
There are also plenty of exciting new opportunities to apply for early detection and diagnosis funding, including engineering-based projects and UK-Africa based partnerships. Applications for our career awards are also open, for which we encourage scientists working in early detection and diagnosis to apply.
Finally, if you are looking for inspiration, scroll down and check out stories of teams who have gone on to achieve success with their funding awards.
Kind regards,
David Crosby
Head of Prevention and Early Detection Research
Cancer Research UK |
|
| | |
|
|
|
|
Upcoming funding deadlines |
|
| | |
|
|
| | More from #EDxConf24 – session chairs confirmed |
| This year’s event will feature Rebecca Fitzgerald and Sarah Mazzilli who will co-chair a session on how biology is informing early detection.
Nima Nabavizadeh and Allan Hackshaw will also chair a session sharing insights on screening trial design, the value of the patient voice and the detection technologies which are making their way to our clinics.
Secure your spot at our conference to be part of exciting conversations in the cancer early detection research sphere.
Follow #EDxConf24 on socials to keep up to date with our agenda. |
| | |
|
|
|
|
|
| | | | | Have you submitted an abstract for our early detection of cancer conference?
We are offering a limited number of bursaries to cover travel and accommodations costs for those with an accepted poster or lightning talk.
The conference hosted by the Canary Center at Stanford in collaboration with OHSU Knight Cancer Institute and us takes place in San Francisco between 22-24 October. | | |
| | | | | | | The Engineering and Physical Sciences Research Council has announced new funding to translate basic engineering and physical science research into impactful healthcare applications.
The awards of up to £1.5 million will be used to address challenges outlined in the health technologies strategy, including transforming prediction and early diagnosis.
It will be mandatory for applicants to partner with healthcare professionals and business partnerships are encouraged.
Applications open on 4 September 2024. | | |
|
|---|
|
|
|
|
| | Funding for UK-Africa projects looking to accelerate innovative technologies |
| Innovate UK are launching a new funding call to create or implement technologies through UK-African partnerships.
The Global Alliance Africa Lead Customer Programme works with applicants that have a letter of endorsement from a key future user in the supply chain.
They are seeking innovations that can move close to commercialisation. |
| | |
|
|
|
|
|
| | | | | Early detection of cancer can save lives, but many breast cancer patients living with a severe disability are not afforded this opportunity as there are no reliable alternatives to screening, with mammography requiring a degree of mobility and upper body strength.
In our latest Cancer News for Researchers article, Roisin Bradley, Consultant Radiologist at York and Scarborough NHS Trust and Jihong Zhu, Director of the Robot-Assisted Living Lab at the University of York’s Institute for Safe Autonomy, talk us through their collaboration which led to an exciting initiative leveraging the power of AI and robotics to enhance the accessibility and accuracy of breast screening.
Using funding from the CRUK Early Detection & Diagnosis Primer Award, they developed an innovative approach which aims to address disparities in breast cancer detection, taking steps to ensure that more patients can benefit from early diagnosis regardless of their geographic location or physical ability. | | |
| | | | | | | Researchers at The Royal Marsden and The Institute of Cancer Research have developed a saliva test that could be a better way to identify men at high risk of prostate cancer than the prostate-specific antigen (PSA) test.
Findings from the BARCODE 1 study, presented at ASCO 2024, calculated the prostate cancer polygenic risk score (PRS) of patients recruited. Of these, 40% of the men with a high PRS score were diagnosed with prostate cancer, a significant increase from those identified by the PSA test. The new test also detected that 55% of the cancers in the study were aggressive, improving on the 36% in detected by the PSA test.
The PRSs were based on 130 genetic variations shown to be linked with prostate cancer. | | |
|
|---|
|
|
|
|
| | Success in Boston, next stop London – save the date for our Cancer Prevention Research Conference |
| The second annual Cancer Prevention Research Conference is taking place in London from 25–27 June 2025.
This follows the sold out first event in Boston where over 350 attendees from all over the world had the opportunity to engage and discuss the latest concepts in cancer prevention research.
Next year’s event will be hosted by Cancer Research UK, in collaboration with the American Cancer Society.
Mark the date in your calendars and register your interest to be amongst the first to hear when registrations open. |
| | |
|
|
|
|
|
| | | | | Our new image campaign – Research is beautiful – is now open for entries. We’re looking for captivating images that showcase your research. It could be your science from the microcosm to the macrocosm; you and your fellow researchers in action; as well as research environments spanning from the lab to research events. Anything that captures your work, or your passion for your work is welcome.
Email us your photos now. T&Cs apply.
Stay tuned to #ResearchIsBeautiful on our social media for our monthly picks. | | |
| | | | | | | Bissan Al-Lazikani (MD Anderson Cancer Center) will be chairing a session on AI and machine learning, focused on how these cutting-edge technologies are shaping brain tumour diagnosis, treatment and patient care.
Join Steven Niederer (Imperial College London/The Alan Turing Institute) and Richard Gilbertson (Cancer Research UK Cambridge Institute), as they delve into the applications of AI in overcoming challenges in drug discovery and development. Steven will share insights and lessons from his work on creating a virtual heart.
Secure a discounted ticket before 9 August to join the conversation and follow #CRUKBrain24 on our social channels for more updates. | | |
|
|---|
|
|
|
|
Cancer Research UK launches new all-in-one clinical research funding scheme |
| We’re introducing a new funding scheme to support more high-quality research that addresses key clinical questions around cancer treatment strategies whilst enhancing our understanding of biological mechanisms. This scheme will replace all our current clinical funding schemes.
Opening in September 2024, the new single, scalable scheme is comprised of three interconnected modules supporting clinical trials of cancer treatment, experimental medicine and sample collection. The flexibility of this modular funding allows you to ask for what you need to do the research you wish to do.
Find out more in our refreshed clinical research statement of intent that sits alongside it. We look forward to receiving your bold and innovative integrated applications to this scheme. |
| | |
|
|
|
Been forwarded this email? Subscribe to our newsletter to stay up to date. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
